Five Scientific Questions: Using the 6-Minute Walk Test (6MWT) to Manage Impedance, Fibrosis, and Battery Life in Adults ≥70 with a Single-Chamber Leadless Pacemaker (LP)
-
Do longitudinal changes in 6MWT performance—distance (6MWD), peak/mean walking heart rate, chronotropic index, and 1-minute HR recovery—predict concurrent trends in LP lead–myocardial interface metrics (RV impedance trajectory, R-wave sensing amplitude, and capture threshold at a fixed pulse width), after adjusting for medications (e.g., β-blockers), electrolytes (K⁺/Mg²⁺), and comorbidity burden?
-
Can a standardized pre-/post-6MWT device check (capture threshold testing and impedance sampling within 2 hours before and after the test) detect exercise-provoked micro-instability at the tissue–electrode interface (early fibrosis/edema signatures) better than resting checks alone, and does such reactivity independently forecast near-term increases in programmed output and modeled battery drain (μAh/day)?
-
Does 6MWT-guided rate-response optimization (randomized crossover: standard vs. individualized accelerometer sensitivity/slope and activity thresholds derived from 6MWT gait cadence and symptom-limited HR targets) reduce average daily pacing output (V@ms × %pacing) and extend modeled longevity (years) without degrading functional capacity (6MWD, Borg RPE) or safety (syncope, arrhythmia burden)?
-
Are biomarkers sampled around the 6MWT—galectin-3, soluble ST2, hs-CRP, NT-proBNP—associated with contemporaneous device metrics (impedance slope, capture threshold drift) in a way that mediates the link between functional limitation (lower 6MWD or slower HR recovery) and accelerated battery consumption, suggesting a fibrosis-inflammation pathway amenable to monitoring via periodic 6MWT?
-
In adults ≥70 with single-chamber LPs, does a 6MWT-anchored clinic pathway (quarterly 6MWT with telemetry review and algorithmic reprogramming rules: e.g., margin minimization if stable capture, RR desensitization if excessive HR at submaximal exertion) lower the 12-month rate of “high-output programming episodes,” slow impedance escalation (Ω/month), and prolong modeled battery life versus usual care?
Scope: These questions are framed to enable prospective cohorts or randomized crossover protocols that pair standardized functional stress (6MWT) with device telemetry, programming interventions, and biologic markers—targeting actionable management of impedance/fibrosis and battery longevity in older LP recipients.